Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

 
• By Joseph Haas
FDA food and drug administration approval health pharmacy certification
Roche gets a third indication for NSCLC drug Alecensa

More from New Products

More from Scrip